Can I stop taking lorlatinib once I take it? Analysis of risk of drug discontinuation and possibility of relapse

Lorlatinib is a third-generation ALK (anaplastic lymphoma kinase) inhibitor mainly used to treat patients with ALK-positive non-small cell lung cancer. Similar to other targeted drugs, the disease control effect of lorlatinib needs to be sustained over the long term to maintain efficacy. However, the risks and likelihood of relapse after discontinuation of medication are issues that patients and physicians need to carefully consider during treatment.

Larlatinib has significant efficacy in the treatment of ALK positive lung cancer, especially in patients who have failed treatment with other ALK inhibitors (such as crizotinib, alectinib). Because its mechanism of action exerts a strong inhibitory effect on ALK gene mutations, if the patient suddenly stops taking the drug, the tumor may become active again, leading to rapid progression of the disease. Many patients have their disease under control and their tumors shrink significantly when treated with lorlatinib. However, once the drug is stopped, especially in the absence of alternative treatments, the tumors may relapse rapidly, affecting survival.

Relapse after discontinuation of treatment is often related to drug resistance. As treatment progresses, tumor cells may gradually adapt to the inhibitory effects of the drug, leading to the generation of new mutations and the formation of drug resistance. Although lorlatinib is often effective in treatment, resistance problems remain. Studies have shown that after drug withdrawal, some patients may develop drug-resistant mutations, causing the drug to lose its effectiveness and allowing tumors to resume growth. This drug resistance usually occurs for a long time after treatment, so patients need regular monitoring and testing so that treatment plans can be adjusted in a timely manner.

Lorlatinib does not have to be taken for life in all cases. In some specific cases, if the patient's condition is completely controlled and there are no obvious signs of tumor progression, the doctor may evaluate whether the drug can be gradually discontinued based on the patient's actual condition. But such decisions need to be made under strict monitoring and clinical evaluation. During the process of drug withdrawal, doctors need to judge whether it is appropriate to discontinue the drug or adjust the treatment method based on the tumor's response and the patient's health status.

Reference link:https://www.lorbrena.com/